pharmaceuticals
pharmaceuticals Articles
Arrowhead Pharmaceuticals saw its shares make a handy gain on Wednesday after the firm presented new data from its midstage study for the treatment of hepatitis B infection.
Published:
Last Updated:
It is no secret that biotech stocks can bring great rewards for investors. They can also deliver serious pain. Fortunately, most of these are currently projected to deliver a solid 2018.
Published:
Last Updated:
One area to look at in this overbought and pricey market is pharmaceuticals. These five now are considered to be “deep value” plays at Merrill Lynch.
Published:
Shares of Teva Pharmaceutical Industries rose Monday after the company announced a reorganization some of its top leadership positions.
Published:
Last Updated:
Achillion Pharmaceuticals saw its shares make a handy gain on Thursday after the company announced a secondary offering.
Published:
Last Updated:
The October 31 short interest data have been compared with the previous figures, and short interest in these selected pharmaceutical stocks decreased.
Published:
Last Updated:
Thanks to progress made in 2017 though, it looks like 2018 could see both a radically new way of delivering antibiotics and finally the first new class approved in 30 years. Here are three companies...
Published:
Last Updated:
Merrill Lynch points to five companies that, in their words, should be key players in the young but growing biosimilar market.
Published:
Last Updated:
Keryx Biopharmaceuticals shares took a hit on Tuesday after the company announced its third-quarter results and an update from the FDA.
Published:
Last Updated:
Drug maker Valeant got a big profit boost from a one-time tax benefit and the company also boosted its EPS guidance and trimmed its revenue guidance for the full year.
Published:
Last Updated:
Cancer drug developer ImmunoGen posted sharply lower profits and revenues than analysts were expecting. The stock is taking a beating as a result.
Published:
Last Updated:
These quarterly numbers are another black eye for Teva Pharmaceutical, sending shares to a low not seen since 2002.
Published:
Last Updated:
Geron is one of the few biopharma winners on Tuesday, with the health care sector in general pushing slightly lower on the day.
Published:
When Pfizer released its third-quarter earnings report before the markets opened on Tuesday, the results and guidance lived up to what analysts expected but weren't enough to placate investors.
Published:
In a decisive move, the Neos Therapeutics board of directors unanimously struck down an acquisition proposal from PDL BioPharma.
Published: